Pliant Therapeutics, Inc. (PLRX)
PLRXNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$0.7996
-0.0101 (-1.25%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $49.51m
- P/E
- –
- EPS, last 4 quarters
- $-1.46
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.7951 to $1.82
- Average volume
- 366.5k
- Previous close
- $0.8097
Analysts
4 coveringUnderperform0 buy, 3 hold, 1 sell
Targets a year out average $2.50, +212.7% from here
Earnings
next estimate $-0.3700Next report
Sep 2025
+18.9%
Dec 2025
+16.7%
Mar 2026
+11.1%
Jun 2026
-9.1%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$28.27m | -$23.58m | -$21.77m | -$23.86m |
| Net income | -$26.30m | -$23.58m | -$20.04m | -$22.37m |
News
8 latest- Pliant Therapeutics Names David Raben As CMO To Lead PLN-101095 Development RTTNews · Oct 1, 2026
- Pliant Wins FDA Fast Track For PLN-101095 In ICI-Refractory Solid Tumors RTTNews · Aug 18, 2026
- RBC Capital Maintains Pliant Therapeutics (PLRX) Sector Perform RecommendationFintel · Nov 7, 2025
- Biotech Stocks Rally After-Hours On Trial Updates, Insider Buys, And Conference Buzz RTTNews · Sep 10, 2025
- Pliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical TrialsQuiver Quantitative · May 1, 2025
- PLIANT THERAPT (PLRX) Upgraded to Buy: Here's What You Should KnowZacks · Apr 10, 2025
- PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should KnowZacks · Mar 27, 2025
- Pliant Reports Early Responses From Phase 1 Dose Escalation Trial With PLN-101095 RTTNews · Mar 17, 2025
The company
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. Pliant's lead program is PLN-101095, an oral, small molecule, dual-selective inhibitor of vß8 and vß1 integrins, that is being developed for the treatment of ICI-refractory advanced or metastatic solid tumors. PLN-101095 is being investigated in FORTIFY, a Phase 1a/1b indication expansion trial enrolling patients with NSCLC, tumors with high tumor mutational burden or clear cell renal cell carcinoma. Pliant's preclinical research is focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules with programs focused on delivering siRNAs to skeletal muscle cells, adipocytes as well as other cell types.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- pliantrx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.